Moderna's Latest Move May be Key to COVID-19 Vaccine Market Dominance

Moderna (NASDAQ:MRNA) may already seem like a market leader. The biotech company's COVID-19 vaccine was only the second to earn an emergency use authorization (EUA) from the Food and Drug Administration, shortly after Pfizer and partner BioNTech garnered one for BNT162b2. In the months since, the U.S. has administered more than 54 million doses of the Moderna vaccine alone. And the Biden administration signed additional deals to buy enough Moderna and Pfizer doses to vaccinate the entire U.S. population.